freeze-thaw comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (lyophilized) | -20°C | Stable for months to years; avoid frost-free freezers |
| Storage temperature (solution) | -80°C | Single-use aliquots preferred; avoid repeated freeze-thaw |
| Reconstitution solvent | Sterile water or buffer | Choice depends on peptide solubility and application |
| Container material | Glass or polypropylene | Low protein-binding surfaces reduce adsorption |
| Shipping condition | Dry ice | Insulated packaging maintains cold chain during transit |
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
Whether an offender displayed viciousness during the time of the commission of the offence of murder; Whether an offender demonstrated a blatant disregard for human life at the time of the killing; and Whether the offender's actions sparked an outrage of the feelings of the community. In Kho's case, the majority three of the five judges were satisfied that Kho, who had used a tree branch to bash Cao's head repeatedly (resulting in a completely shattered skull that caused Cao to die in a coma six days after the attack), had demonstrated both a blatant disregard for human life and viciousness while committing the crime, and Kho's actions were such that they had outraged the feelings of the community. Due to this, Kho was once again given the death penalty and he was eventually hanged on 20 May 2016, at 3:30 pm after his appeal for a stay of execution was dismissed that same morning, a rare occurrence of an execution not carried out at dawn on Friday. Consequently, the guiding principles from Kho's case also impacted several subsequent murder cases and influenced the sentencing or appeal outcomes of these murder cases, which include the 2010 Kallang slashing, the 2016 Gardens by the Bay murder, the 2016 Circuit Road murder, the 2016 Azlin Arujunah case and the 2013 murder of Dexmon Chua Yizhi, etc.
=== American Cancer Society === Inhorn's ongoing interest in cervical cancer was the reason that he joined the American Cancer Society, Wisconsin Division, in 1967. He was Chair of the State Cancer Prevention Study II, and in 1986, he headed a demonstration project with a number of Wisconsin hospitals to determine the acceptance of offering low-cost mammography as a screening test for breast cancer. Inhorn served as President of the Wisconsin Division from 1970 to 1972, continuing on the board until 2010. He also served on the national American Cancer Society Board from 1982 to 1990.
=== United States === Acetorphine is a Schedule I controlled substance in the United States. Its DEA Administrative Controlled Substances Control Number is 9319 and the one salt in use, acetorphine hydrochloride, has a freebase conversion ratio of 0.93.
=== Economics === Estimated costs for a 12-week treatment of elbasvir/grazoprevir are upwards of $54,600. Other treatments that work in a similar manner have effectively more costs. Some treatments for Hepatitis C are on the cheaper side, in some instances as low as $8,400. Additional ribavirin costs can add between $500 and $900. These cheaper prescriptions are however interferon-based treatments and do not target every genotype of the HCV. These regimens were the priority treatment before 2011. Two examples of these treatments are alfa-2a and alfa-2b costing $9250 and $8400, respectively.
Sources: en.wikipedia.org
== Signs and symptoms == The hallmark of polymyositis is weakness and/or loss of muscle mass in the proximal musculature, as well as flexion of the neck and torso. These symptoms can be associated with marked pain in these areas as well. The hip extensors are often severely affected, leading to particular difficulty in climbing stairs and rising from a seated position. The skin involvement of dermatomyositis is absent in polymyositis. Dysphagia (difficulty swallowing) or other problems with esophageal motility occur in as many as 1/3 of patients. Low grade fever and enlarged lymph nodes may be present. Foot drop in one or both feet can be a symptom of advanced polymyositis and inclusion body myositis. The systemic involvement of polymyositis includes interstitial lung disease (ILD) and heart disease, such as heart failure and conduction abnormalities. Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness often noted in the upper legs due to early fatigue while walking. Sometimes the weakness presents itself as an inability to rise from a seated position without help or an inability to raise one's arms above one's head. The weakness is generally progressive, accompanied by lymphocytic inflammation (mainly cytotoxic T cells).
In this age group, lorazepam is associated with falls and hip fractures. Due to these concerns, lorazepam use is generally recommended for at most four weeks. Lorazepam was initially patented in 1963 and went on sale in the United States in 1977. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 100th most commonly prescribed medication in the United States, with more than 6 million prescriptions.
== Dietary recommendations == According to US & Canadian Dietary Reference Intake guidelines, women ages 19–70 need to consume 46 grams of protein per day while men ages 19–70 need to consume 56 grams of protein per day to minimize risk of deficiencies. These Recommended Dietary Allowances (RDAs) were calculated based on 0.8 grams protein per kilogram body weight and average body weights of 57 kg (126 pounds) and 70 kg (154 pounds), respectively. However, this recommendation is based on structural requirements only and disregards use of protein for energy metabolism. This requirement is for a normal sedentary person. In the United States, average protein consumption is higher than the RDA. According to results of the National Health and Nutrition Examination Survey (NHANES 2013–2014), average protein consumption for women ages 20 and older was 69.8 grams and for men 98.3 grams/day. According to research from Harvard University, the National Academy of Medicine suggests that adults should consume at least 0.8 grams of protein per kilogram of body weight daily, which is roughly equivalent to a little more than 7 grams for every 20 pounds of body weight. This recommendation is widely accepted by health professionals as a guideline for maintaining muscle mass, supporting metabolic functions, and promoting overall health.
Sources: en.wikipedia.org
Natalie Paige Cochran (born November 1980) is an American former pharmacist and murderer. She is from Raleigh County, West Virginia. She is known for her convictions related to fraud and the murder of her husband, Michael Brandon Cochran.
Etomethazene (5-methyldesnitroetonitazene, 5-methyl etodesnitazene, Eto) is a benzimidazole derivative with opioid effects which has been sold as a designer drug over the internet since 2022, first being definitively identified in Sweden in January 2023. It is an analogue of etonitazene where the nitro (NO2) group has been replaced by a methyl (CH3) group. It is less potent than etonitazene itself but still has around twice the potency of fentanyl. Etomethazene has a relatively short duration of action of about 120 min.
List of ICD-9 codes 001–139: infectious and parasitic diseases List of ICD-9 codes 140–239: neoplasms List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders List of ICD-9 codes 280–289: diseases of the blood and blood-forming organs List of ICD-9 codes 290–319: mental disorders List of ICD-9 codes 320–389: diseases of the nervous system and sense organs List of ICD-9 codes 390–459: diseases of the circulatory system List of ICD-9 codes 460–519: diseases of the respiratory system List of ICD-9 codes 520–579: diseases of the digestive system List of ICD-9 codes 580–629: diseases of the genitourinary system List of ICD-9 codes 630–679: complications of pregnancy, childbirth, and the puerperium List of ICD-9 codes 680–709: diseases of the skin and subcutaneous tissue List of ICD-9 codes 710–739: diseases of the musculoskeletal system and connective tissue List of ICD-9 codes 740–759: congenital anomalies List of ICD-9 codes 760–779: certain conditions originating in the perinatal period List of ICD-9 codes 780–799: symptoms, signs, and ill-defined conditions List of ICD-9 codes 800–999: injury and poisoning List of ICD-9 codes E and V codes: external causes of injury and supplemental classification
Sources: en.wikipedia.org
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.
Solutions are typically stored at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles. They should be protected from light and kept in low-binding containers. Some peptides require a carrier protein or cryoprotectant to prevent adsorption and aggregation.
Records should include the lot number, date received, storage temperature, and any handling steps. A log of freeze-thaw cycles and aliquot preparation helps track stability. This documentation supports traceability and quality control.
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.